metaEvidence - overview


			deaths (OS)
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus pembrolizumab plus placebo
	pembrolizumab plus ipilimumab vs. pembrolizumab plus placebo	1	70 [-751; 892] /10000 137/284 vs. 135/284
versus pemetrexed plus platin
	nivolumab plus ipilimumab vs. pemetrexed plus platin	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	3	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	cemiplimab vs. Standard of Care (SoC)	1	-1277 [-2034; -519] /10000 70/283 vs. 105/280
	durvalumab alone vs. Standard of Care (SoC)	1	-1275 [-2235; -316] /10000 108/163 vs. 128/162
	durvalumab plus tremelimumab vs. Standard of Care (SoC)	1	-969 [-1914; -23] /10000 113/163 vs. 128/162
	nivolumab alone vs. Standard of Care (SoC)	2	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	pembrolizumab alone vs. Standard of Care (SoC)	4	NaN [NaN; NaN] /10000 0/0 vs. 0/0